Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.
You may also be interested in...
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Daiichi will pay $4.6 billion for stake in generics marketer.
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Daiichi will pay $4.6 billion for stake in generics marketer.
Booming Clinical Research Business Could Trigger Regulatory Overhaul In India
Indian contract research market may hit $300 million by 2010, U.S. pharma exec says.